The Harmonized System (HS) code 30049049 pertains to pharmaceutical products, specifically medications in measured doses. Tariff rates for this code vary across countries and are influenced by Most Favored Nation (MFN) rates, Free Trade Agreements (FTAs) with India, and exemptions for essential medicines.
Brazil: As a member of the World Trade Organization (WTO), Brazil applies MFN tariff rates to imports. While specific MFN rates for HS code 30049049 are not readily available, Brazil's tariff schedule generally imposes duties on pharmaceutical products. India and Brazil are both members of the BRICS group, but no bilateral FTA exists between them, so preferential rates are not applicable. However, Brazil's health regulations may provide exemptions or reduced tariffs for essential medicines, including certain cancer treatments like Gefitinib.
Iraq: Iraq's tariff regime includes MFN rates for WTO members. Specific MFN rates for HS code 30049049 are not specified in the available data. Iraq does not have an FTA with India, so no preferential rates apply. Nonetheless, Iraq's Ministry of Health may offer exemptions or reduced tariffs for essential medicines to ensure affordability and accessibility.
Philippines: As a member of the Association of Southeast Asian Nations (ASEAN), the Philippines benefits from the ASEAN-India Free Trade Area (AIFTA). Under this agreement, tariffs on pharmaceutical products, including those under HS code 30049049, are often reduced or eliminated. Additionally, the Philippines' Food and Drug Administration may classify certain medications as essential, potentially qualifying them for further exemptions or reduced tariffs.
Russia: Russia, a WTO member, applies MFN tariff rates to imports. Specific MFN rates for HS code 30049049 are not detailed in the available sources. There is no FTA between Russia and India, so preferential rates are not applicable. However, Russia's Ministry of Health may provide exemptions or reduced tariffs for essential medicines, including cancer treatments like Gefitinib.